Quarterly ResultMay 8, 2026, 07:03 AM
Tvardi Therapeutics Q1 Net Loss $(6.8)M; TTI-109 Data in June
AI Summary
Tvardi Therapeutics reported a net loss of $(6.8) million for Q1 2026, an improvement from $(9.6) million in Q1 2025, with a net loss per share of $(0.73). The company anticipates topline data from its TTI-109 healthy volunteer study in June 2026, which will inform its clinical development strategy. Topline results for the TTI-101 Phase 2 HCC trial are expected in 2H 2026, and the cash runway is projected to fund operations into Q4 2026.
Key Highlights
- Net loss for Q1 2026 was $(6.8) million, compared to $(9.6) million in Q1 2025.
- Basic and diluted net loss per share was $(0.73) for Q1 2026, versus $(3.72) in Q1 2025.
- Research and development expenses increased to $4.9 million in Q1 2026 from $3.1 million in Q1 2025.
- Cash, cash equivalents, and short-term investments totaled $25.0 million as of March 31, 2026.
- Cash runway is expected to fund operations through clinical readouts and into Q4 2026.
- Topline data for TTI-109 healthy volunteer study anticipated in June 2026.
- Topline results for TTI-101 Phase 1b/2 HCC trial on track for 2H 2026.
- TTI-101 Phase 2 IPF trial showed a 9.4% reduction in fibrosis score vs 2.4% for placebo.